Partner Headlines - CPHD

  1. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga
  2. Leading Medical Stock Cepheid Trying To Break Out

    IBD
  3. Benzinga's Top Upgrades

    Benzinga
  4. Bank of America Upgrades Cepheid To Buy

    Benzinga
  5. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga
  6. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD
  7. Cepheid Receives FDA Clearance For Xpert Norovirus, The First ...

    Benzinga
  8. CEPHEID

    IBD
  9. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  10. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  11. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  12. Stocks Fight Back To Finish Mixed

    IBD
  13. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  14. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  15. CEPHEID

    IBD
  16. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  17. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  18. CEPHEID

    IBD
  19. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  20. Alexion Takes Off On Outlook

    IBD
  21. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  22. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  23. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  24. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  25. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  26. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  27. Benzinga's Top Downgrades

    Benzinga
  28. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  29. Benzinga's Top Downgrades

    Benzinga
  30. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  31. Cepheid Announces Board of Directors Changes

    Benzinga
  32. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  33. Medtech Stocks Moving As Conference Makes Waves

    IBD
  34. Medtech Stocks Moving As Conference Makes Waves

    IBD
  35. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  36. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  37. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  38. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  39. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  40. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  41. Stocks To Watch For December 28, 2012

    Benzinga
  42. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  43. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  44. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  45. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  46. Benzinga's Top Downgrades

    Benzinga
  47. Benzinga's Top Upgrades

    Benzinga
  48. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  49. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  50. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  51. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  52. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  53. Benzinga Mid-Afternoon Market Update

    Benzinga
  54. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  55. Benzinga Mid-Day Market Update

    Benzinga
  56. Mid-Morning Market Update

    Benzinga
  57. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  58. Benzinga's Top Initiations

    Benzinga
  59. A Peek Into The Market Before The Trading Starts

    Benzinga
  60. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  61. Benzinga's Top Initiations

    Benzinga
  62. Technology Sector Wrap

    FoxBusiness
  63. Technology Sector Wrap

    FoxBusiness
  64. Technology Sector Wrap

    FoxBusiness
  65. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  66. Cepheid Down 20% on Weak Guidance

    Benzinga
  67. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  68. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  69. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  70. A Peek Into The Market Before The Trading Starts

    Benzinga
  71. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  72. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  73. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  74. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  75. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  76. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  77. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  78. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  79. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  80. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  81. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  82. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  83. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  84. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  85. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  86. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center